List of Material Transactions
| Number | Name | Overview | Date Notice Received by DOH | Transaction Closing Date | Summary | Impact-Groups/Individuals | Impact-Services Currently Provided | Commitments by the Parties to Mitigate Potential Impacts | Summary of Public Comment(s) Regarding the Transaction |
|---|---|---|---|---|---|---|---|---|---|
| 27 |
|
A holding company is forming a secondary holding company to transfer the interests of certain entities that provide technology-enabled network management services for Durable Medical Equipment, Prosthetics, Orthotics, and Supplies (DMEPOS). | 2/28/2026 | 3/31/2026 | Tufts Associated Health Maintenance Organization (HMO) will sell the stock of Integra Partners Holdings to Integra Acquisition. Integra Acquisition is a holding entity that is newly formed for the purposes of this transaction. The purpose of this transaction is to expand access to technology-enabled network management services for Durable Medical Equipment, Prosthetics, Orthotics, and Supplies (DMEPOS) providers and payor clients. Integra Partners is an independent network manager and intermediary for Orthotics, Prosthetics, and Durable Medical Equipment providers. They work with their partners to streamline administrative costs and improve efficiency by managing provider contracts, claims, and utilization management. Integra was started in New York but now provides services to over 18 million members across 26 states. Integra Partners is headquartered in New York but does not operate any physical locations in New York. Tufts Associated Health Maintenance Organization, Inc. is a health plan that provides coverage, care, and services to more than half a million members in Massachusetts and Rhode Island. In 2015, Tufts Health Plan acquired Integra Partners to manage its DMEPOS services to improve network management, claims, and utilization management. In 2021, Harvard Pilgrim Health Care and Tufts Health Plan combined to create Point32Health. |
The parties state that this transaction will improve the efficiency and coordination of the management systems to support better in-home healthcare outcomes across patient populations that the DMEPOS providers service. | The parties state that they do not provide direct medical services to patients, therefore no impacts are anticipated. | The parties state that there are no commitments to mitigate potential impacts. | |
| 26 |
|
Arlozorov9, Inc. d/b/a Alma, a New York-based digital administration platform for mental health providers, is being acquired by Spring Care, Inc. d/b/a Spring Health, which is a New York-based, employer-sponsored behavioral health platform that relies on Artificial Intelligence (AI) programming for certain non-clinical tasks. | 3/10/2026 | The parties state that the transaction is expected to close early in the second quarter of 2026. | Spring Care, Inc. d/b/a Spring Health ("Spring Health" or the "Buyer") will acquire all the outstanding capital stock and the vested and unvested rights to acquire capital stock of Arlozorov9, Inc. d/b/a Alma ("Alma" or the "Seller"). The parties state that the purpose of the transaction is to create an entity with stronger connections to employers, health insurers, and providers to enhance the Parties' ability to deliver behavioral health care to patients. Clinical services networked through Spring Health and Alma are fully virtual and have no physical locations in New York. Spring Health is a New York-based, behavioral health platform providing therapy, psychiatry, and care navigation services for patients through employer-sponsored programs. The platform is supported by Artificial Intelligence (AI)/machine-learning tools to analyze data, which is then used to match individuals with mental health providers and track clinical outcomes to inform ongoing care. Spring Health also integrates digital tools such as assessments and progress monitoring to streamline access to care and support employers in managing workforce mental health. Alma is a Brooklyn, New York-based digital platform that provides administrative and billing support to independent mental health providers. It works with therapists to enable participation in insurance networks by managing claims, payments, and payer relationships, while also offering basic practice management tools. Alma's model focuses on reducing administrative burden for providers and expanding patient access to in-network mental health services. |
The parties state that no changes in health care services are anticipated in connection with the proposed transaction. | The parties state that there are no impacts on services anticipated as a result of the transaction. | The parties state that there are no impacts anticipated as a result of the transaction. | |
| 25 | Buyer:
Sellers:
|
A national laboratory services company is acquiring select assets of a New York-based laboratory company, with 13 locations in Central New York. | 1/28/2026 | March 2026 | Laboratory Corporation of America Holdings ("Labcorp") has entered into an agreement with Crouse Health Hospital, Inc. ("Crouse Hospital") and Laboratory Alliance of Central New York, LLC ("Lab Alliance") to acquire select assets Crouse Hospital and Lab Alliance's clinical laboratory business, including select patient service centers in Central New York. Labcorp is a clinical laboratory company, headquartered in Burlington, North Carolina, that provides diagnostic, genomic, specialty, and drug-development testing. It has over 140 New York patient service center locations across New York State, with a high concentration in NYC. Labcorp's services include routine blood work, oncology, genetic testing, infectious disease panels, occupational health testing. It also provides support for clinical trials. Crouse Hospital is a not-for-profit hospital based in Syracuse, providing a wide range of medical and surgical services to patients across Central and Northern New York. It is licensed for 506 acute-care adult beds and 57 bassinets and serves more than 23,000 inpatients, 56,000 emergency visits, and over 600,000 outpatient visits annually across a 16-county region. Lab Alliance is an independent, for-profit clinical and anatomic pathology laboratory serving hospitals, physician practices, and patients with 13 locations across upstate New York. It provides comprehensive diagnostic testing services and supports regional healthcare delivery through its laboratory facilities and patient service centers. As a result of the transaction, Lab Alliance will close its laboratory and Labcorp plans to absorb the volume of patients and providers who previously used the Lab Alliance locations. The parties indicated that, because Labcorp maintains a substantially broader payor portfolio and participates with the same payors as those contracted by Lab Alliance, the transaction is not expected to result in adverse effects related to the termination of services by Lab Alliance. The Department notes, however, that the transaction may result in negative impacts associated with workforce changes and reductions at Lab Alliance locations. |
The parties state that no adverse impacts are anticipated to patients or health care providers. The Department notes, however, that there is an anticipated negative impact related to Lab Alliance's anticipated employment changes, which are planned post-transaction closure. | The parties state that no adverse impacts are anticipated, and that the proposed transaction will allow continued access to laboratory testing services and technologies for Lab Alliance's patients. | The parties state that there are no anticipated adverse impacts associated with the transaction, but they are committed to monitoring and addressing any such impacts should they arise. | |
| 24 |
|
A U.S.-based multinational healthcare company is acquiring a national company that produces cancer screening products. The acquired company will continue to operate as a subsidiary of the acquiring company post transaction. | 1/17/2026 | 3/23/2026 | Abbott Laboratories ("Abbott") will acquire Exact Sciences Corporation ("Exact Sciences") in a transaction whereby a wholly owned subsidiary of Abbott, Badger Merger Sub I, Inc. ("Merger Sub") will merge with and into Exact Sciences, with Exact Sciences surviving the merger as a wholly owned subsidiary of Abbott. The parties are pursuing the transaction to accelerate innovation and expand access to diagnostics focused on advanced cancer screening, with a goal to help more people detect and manage cancer during its earliest stages. The parties state that the transaction will enable Abbott to enter the fast-growing health sector of advanced cancer diagnostics, serving millions more people. Abbott Laboratories is a global healthcare company that focuses on medical devices, diagnostics, nutrition, and pharmaceuticals. Abbott Laboratories does not operate any physical locations in New York, but they provide services in over 160 countries. Abbott Laboratories' products and services include nutrition products, biowearables for diabetes management, cardiovascular products such as stents, and generic-branded medications. Some popular brands that are owned by Abbott Laboratories are Pedialyte, Similac, and Ensure. Exact Sciences is a United States based molecular diagnostics and cancer screening company. Exact Sciences does not operate any physical locations in New York, but they provide services to over 120 countries. Exact Sciences creates products to detect cancer early, help guide treatment plans, and provide monitoring during and after cancer treatments and diagnoses. Exact Sciences produces products for general early cancer detection (Cancerguard), early detection for colon cancer (Cologuard), and early detection of liver cancers (Oncoguard Liver Test). |
The parties state that they do not anticipate any material impacts on any groups or individuals as a result of the transaction. | The parties state that all of the services currently provided by Exact Sciences are expected to continue uninterrupted following the transaction, with no impact on cost, quality, access, health equity, or competition. | The parties state that there are no commitments to mitigate potential impacts as no adverse impacts are expected as a result of the transaction. | |
| 23 | Buyer:
Sellers:
|
A national laboratory services company is acquiring select assets of a New York-based laboratory company, with 13 locations in NYC. | 12/5/2025 | February 2026 | Laboratory Corporation of America Holdings ("Labcorp") has entered into an agreement with Empire City Laboratories, Inc., Steve Nisan, Nisan 2020 Family Trust, and Michael Nisan (collectively, "Empire City Laboratories") to acquire select assets of Empire City Laboratories' clinical laboratory business, including select patient service centers in New York City. Labcorp is a clinical laboratory company, headquartered in Burlington, North Carolina, that provides diagnostic, genomic, specialty, and drug-development testing. It has over 140 New York patient service center locations across New York State, with a high concentration in NYC. Labcorp's services include routine blood work, oncology, genetic testing, infectious disease panels, occupational health testing. It also provides support for clinical trials. Empire City Laboratories is a clinical laboratory company headquartered with 13 New York patient service centers that are primarily located in Brooklyn and Queens. It provides a variety of diagnostic services ranging from routine blood work, allergy testing, and advanced specialty diagnostic tests. As a result of the transaction, Empire City Laboratories will close its laboratory and will potentially close one or more of its patient service center locations. Labcorp plans to absorb the volume of patients and providers who previously used the Empire City Laboratories locations, and if there is a need for additional capacity, Labcorp intends to open new patient service centers in the same geographic location there was an Empire City Laboratories patient service center. LabCorp has coverage in each area that Empire City Labs has patient service locations, including 3 in the Bronx, 11 in Brooklyn, 17 in New York City, and 6 in Queens. The parties indicated that, because Labcorp maintains a substantially broader payor portfolio and participates with the same payors as those contracted by Empire, the transaction is not expected to result in adverse effects related to the termination of services by Empire. The Department notes, however, that the transaction may result in negative impacts associated with workforce reductions at Empire City Laboratories locations that are closing. |
The parties state that no adverse impacts are anticipated to patients or health care providers. The Department notes, however, that there is an anticipated negative impact related to Empire City Laboratories' anticipated employee layoffs planned for post-transaction closure. | The parties state that no adverse impacts are anticipated, and that the proposed transaction will allow continued access to laboratory testing services and technologies for Empire City Laboratories' patients. | The parties state that there are no anticipated adverse impacts associated with the transaction, but they are committed to monitoring and addressing any such impacts should they arise. | |
| 22 |
|
A new limited liability company is acquiring indirect equity ownership and control of a management services organization (MSO). The MSO provides management and other non-clinical services to 74 physician practices across New York, including in New York City and Westchester, that specialize in intraoperative neuromonitoring. | 12/22/2025 | 3/13/2026 | Sparta HoldCo, LLC, a newly formed affiliate of PPC Enterprises, LLC ("PPC"), will acquire indirect equity ownership and control of the Accurate Entities. The parties state that this acquisition is intended to enhance PPC's administrative service capabilities and create operational efficiencies for both the Accurate Entities and the physician practices they support. The Accurate Entities, comprising Accurate Monitoring Holdings, LLC and its subsidiaries Accurate Monitoring, LLC and Accurate Neuromonitoring SE, LLC, provide administrative and back-office support services to physician practices specializing in intraoperative neurophysiologic monitoring, which involves the real-time assessment of neural pathway function during surgical procedures to help reduce the risk of neurologic injury. The Accurate Entities manage billing, scheduling, and other operational functions to support the clinical activities of these physician practices, including Neurophysiological Interpretive Medicine, PLLC ("NIM"). NIM is a physician-led practice specializing in intraoperative neurophysiological monitoring managed by the Accurate Entities. NIM operates out of 74 locations in New York State, primarily across New York City and Westchester. NIM provides real-time neurophysiological interpretation and guidance during surgical procedures, which helps surgeons preserve neural function during surgery in order to minimize the risk of injury and improve patient outcomes. Sparta HoldCo, LLC is a newly formed affiliate of PPC that states it was created to acquire and manage the Accurate Entities. This acquisition is intended to enhance PPC's administrative service capabilities, streamline operations, and create efficiencies across the Accurate Entities and the physician practices they serve. |
The parties state that there are no groups/individuals likely to be impacted by the transaction. | The parties state that they do not anticipate any impact to cost, quality, health equity or competition, since no services will be reduced or eliminated as a result of this transaction. | The parties state that there are no commitments to mitigate potential impacts since they do not anticipate any adverse impacts as a result of this transaction. | |
| 21 |
|
A company that owns a management services organization (MSO) is being acquired by a newly formed company. The MSO provides administrative and back-office support to physician practices, including a group that has 13 locations in New York and specializes in venous services. | 12/16/2025 | 3/2/2026 | MVC Holdings, LLC owns MVC MSO, LLC, a management service organization that provides administrative and back-office support services to physician practices that specialize in venous services. One of these practices is New Jersey Medical Services Group, LLC, which has several locations in New York State. MVC Acquisition, LLC is a newly formed entity created to effectuate the transaction, and it is majority-owned by AEA Elevate. Through this transaction, MVC Acquisition, LLC will acquire a majority of the ownership of MVC Holdings, LLC. New Jersey Medical Services Group LLC is commonly known as Metro Vein Centers (MVC) and it operates 63 locations across seven states and specializes in the treatment of varicose and spider veins. In New York, MVC maintains 13 locations in the Bronx, Brooklyn, Long Island, Manhattan, Queens, Staten Island, Westchester, and Yonkers. Services provided include compression therapy, laser treatments, and injectable medicines. The parties state that the purpose of the transaction is to expand MVC's venous care providers and enhance the patient experience. The parties also state that they aim to enhance clinical care and the patient experience through technology enablement, and to offer venous services to a broader patient population by expanding MVC's network of providers. |
The parties state that the transaction involves the acquisition of a majority of the interests in MVC and it does not involve the transfer of clinical assets, provider contracts, or patient care responsibilities. As such, the parties state that they do not anticipate impacts as a result of the transaction. | The parties state that all the services they offer are expected to continue uninterrupted following the closing of the transaction. | The parties state that the transaction involves the acquisition of a majority of the interests in MVC and it does not involve the transfer of clinical assets, provider contracts, or patient care responsibilities. As such, the parties state that they do not anticipate impacts as a result of the transaction. | |
| 20 |
|
The assets of Bethpage Medical, PLLC d/b/a Garden OB/GYN and Michael Terrani, M.D., P.C., an obstetrics/gynecology practice with 11 New York locations across Manhattan, Queens, Brooklyn, and Long Island, is being acquired by a New York hospital-affiliated university faculty practice corporation, NSUH Plainview Physicians UFP Corporation. | 12/12/2025 | 1/12/2026 | NSUH Plainview Physicians UFP Corporation ("NSUH" or the "Buyer") will purchase substantially all of the assets of Bethpage Medical, PLLC d/b/a Garden OB/GYN and Michael Terrani, M.D., P.C. (together, the "Seller). Following the transaction, the Seller's obstetrics/gynecology and women's health services are expected to continue to be provided at the existing practice locations under the Buyer's ownership. The parties state that the purpose of the transaction is to allow the Buyer to expand access to high-quality obstetrics/gynecology and women's health services in the communities currently served by the Buyer and the Seller. NSUH is a New York-based university faculty practice corporation affiliated with North Shore University Hospital and Plainview Hospital, both of which are part of the Northwell Health system. NSUH is part of an academic medical system and supports the delivery of patient care, medical education, and clinical integration within the hospital-affiliated network. NSUH provides physician services primarily in obstetrics/gynecology. Bethpage Medical, PLLC d/b/a Garden OB/GYN is a medical practice specializing in obstetrics/gynecology and women's health with 11 New York State locations in Manhattan, Queens, Brooklyn and on Long Island. Michael Terrani, M.D. is the director of medical practice at Garden OB/GYN and is an obstetrician-gynecologist and researcher focused on total fetal care, preterm birth, and stillbirth prevention. |
The parties anticipate that the transaction will have no material impact to the public regarding site closures, layoffs, and there will be minimal, if any, impact on plan network participation. The parties note that all but two healthcare plans will be continued post-closing (those not continued will be two PPO plans with minimal patient participation, estimated to be <140 patients/year). | The parties anticipate that the transaction will have no material impact to the public regarding alteration of facility services. Although, the Seller's laboratory will cease operations following this transaction, the current laboratory services will be provided by a laboratory maintained by the Buyer or an affiliate. | The parties state the Buyer intends to offer the same services the Seller now offers at its current locations; therefore, no impacts are expected as a result of the transaction. | The Department received one public comment regarding this transaction from a plaintiff in a civil action against transaction parties Bethpage Medical, PLLC d/b/a Garden OB/GYN and Michael Terrani, M.D., P.C. The commenter stated that the proposed transaction appeared to be structured to transfer substantially all assets, goodwill, patient relationships, personnel, and continuity of medical services, while leaving behind known creditor and malpractice liabilities. The commenter expressed concern that the transaction poses a risk to patients and judgement creditors, and could impair claimants' rights. |
| 19 |
|
A physician-led management services organization (MSO) is entering into an agreement with the physician owners of four New York-based medical practices. The MSO will provide management and other non-clinical services to each practice. | 10/31/2025 | Transaction will not close sooner than 12/1/2025 | NE Ortho Management Services, LLC d/b/a Evolve Orthopedic Partners ("Evolve") is a physician-led management services organization (MSO) entering into agreements with the physician owners of (1) New York Anesthesiology Medical Specialties, P.C. ("NYAMS"), d/b/a New York Spine & Wellness Center; (2) Syracuse Orthopedic Specialists, P.C. ("SOS"); (3) Heritage One Day Surgery, LLC ("HODS"); and, (4) Specialists' One-Day Surgery, LLC ("SODS"). Evolve will purchase substantially all of the non-clinical assets of SOS and NYAMS and provide management and other non-clinical services to those practices. HODS and SODS will transfer all of their non-clinical assets into an administrative services organization to be jointly owned by Evolve and the physician owners of SOS and NYAMS. Evolve was created to support orthopedic and ambulatory surgery practices by managing their non-clinical operations. NYAMS is a pain management specialty practice that employs 25 providers across 6 locations in Syracuse and Camillus. SOS is a Central NY-based practice specializing in orthopedic care and surgery. SOS employs 24 providers across 13 locations in Syracuse and Camillus and provides services including urgent care, specialized surgery, and pain management. HODS and SODS are ambulatory surgery centers (ASCs). HODS is an ASC that has 11 providers in North Syracuse and provides outpatient non-operative spine procedures. SODS is an ASC in East Syracuse that provides same day surgery for patients, including procedures such as carpal tunnel surgery, lumbar and cervical injections, and rotator cuff repair. |
The parties state that the transaction will not have any adverse impact on groups or individuals regarding cost, quality, access, health equity,or competition in the markets currently served. The parties state it is expected that this transaction will maintain or improve cost, quality, access, health equity and competition. | The parties state that they currently provide orthopedic surgery and pain management professional and facility services through their medical practices and affiliated ambulatory surgery centers. The parties state no negative impacts on the quality, scope or delivery of such services are expected as a result of this transaction. | The parties state that given there are no anticipated adverse impacts of the transaction and, therefore, the transaction does not involve commitments to mitigate adverse impacts. However, the parties expect the transaction to result in the preservation and expansion of clinical services by the practice due to the operational efficiencies that will be achieved. | |
| 18 | Buyer parties:
Seller parties:
|
A U.S.-based investment company is indirectly purchasing 100% of the stock of a national home infusion provider that has two physical locations in New York State. | 10/06/2025 | 1/30/2026 | NP Kaba Parent, Inc., an affiliate of Nautic Partners, LLC ("Nautic"), will acquire 100% of the shares of stock of NH Kronos Parent, Inc. ("Target"). Target provides adult and pediatric home infusion care services through a collection of its wholly-owned subsidiaries operating as KabaFusion. KabaFusion is a national company with several locations in the northeast, including two sites in New York State operated by KabaFusion NY, LLC. One site is located in Syracuse, and the other in Albany. It offers a range of home infusion therapies including those that treat immune-related nervous system diseases and dermatological diseases. It also provides nutritional therapy and intravenous antibiotics. NP Kaba Parent, Inc. is a corporate entity established to facilitate the acquisition, ownership, and operation of healthcare services businesses. NP Kaba Parent is affiliated with Nautic Partners, a firm that partners with companies in healthcare and other sectors. Following the transaction, NP Kaba Parent, Inc. will assume full ownership of NH Kronos Parent, Inc. and its subsidiaries, including those operating as KabaFusion. |
The parties state that there are no anticipated adverse impacts of the transaction on cost, quality, access, health equity or competition. | The parties state that there are no plans to reduce or eliminate existing services and/or participation in specific networks as a result of the transaction. | The parties state this question is not applicable, given that the parties do not anticipate any adverse impacts of the transaction. | |
| 17 |
|
A Delaware-based holding company is selling a management services organization (MSO) to another Delaware-based holding company, which already owns an MSO. The MSOs provide administrative and back-office support services to 38 physician practices in New York State. | 10/2/2025 | 11/3/2025 | Urology Partners Co., L.P., a Delaware limited partnership, is selling the ownership and control of Solaris Health Holdings, LLC, a management service organization (MSO), to the GI Alliance Holdings, LLC. Solaris Health Holdings provides administrative and back-office support services to physician practices that specialize in urology services, including urine incontinence therapies, genetic testing, and chronic care management. Solaris Health has 38 locations across the New York metropolitan area, in the Bronx, Queens, Long Island, and Manhattan. The New York locations managed by Solaris Health operate under the name Integrated Medical Professionals, PLLC. GI Alliance Holdings provides practice management support for over 900 independent gastroenterologists across 345 practices in the US. Nationally, GI Alliance Holdings partners with physician practices that offer a wide range of gastroenterology services including pediatric gastroenterology, endoscopies, and colonoscopies. GI Alliance Holdings has one gastroenterology practice in New York State, Gastroenterology Group of Rochester, LLP., located in Rochester. Solaris Health Holdings works with over 750 providers across 250 practices in 14 states. The parties state that this partnership expands Solaris Health's ability to collaborate with a larger network of urology providers, allowing physicians to optimize care delivery and enhance patient access. In 2024, GI Alliance acquired a majority stake in Cardinal, which reported over $226 B in revenue in fiscal year 2024. |
The parties state that there are no anticipated adverse impacts of the proposed transaction on cost, quality, access, health equity, or competition. | The parties state that there are no anticipated adverse impacts of the proposed transaction on cost, quality, access, health equity, or competition. | The parties state that this question is not applicable. | |
| 16 |
|
A New York City-based plastic surgery practice with two locations is entering into an administrative services agreement under which it will sell its non-clinical assets and receive administrative support from a management group. Ownership in the practice will also be consolidated under Dr. Eric Schweiger. | 9/11/2025 | 10/31/2025 | This transaction has two parts: First, Neinstein Plastic Surgery, PLLC ("Practice"), a physician-owned plastic surgery practice, will transfer all its non-clinical assets to SDG Management Company, LLC ("SDG") and enter into an administrative services agreement with SDG. At the same time, Dr. Eric Schweiger will buy the ownership interests of Drs. Ryan Neinstein and Chris Funderburk in the practice, making him the sole owner. Under the administrative services agreement, SDG will provide non-clinical and administrative support to the practice. Neinstein Plastic Surgery, PLLC has two locations in New York City and offers a range of aesthetic procedures such as liposuction, body contouring, and breast augmentation. Dr. Eric Schweiger is the founder and CEO of Schweiger Dermatology Group, which has 160 offices on the East Coast, including in New York, Connecticut, and Florida. Neinstein Plastic Surgery, PLLC operates on a fee-for-service (private-pay) basis, so it does not participate in-network with any third-party payors, including Medicare, Medicaid, or commercial plans. The parties state that the purpose of the transaction is to facilitate the sale of the practice while improving the practice's operational efficiencies and allowing clinical providers to focus more fully on patient care by outsourcing non-clinical business operations to SDG. |
The parties state that there are no anticipated adverse impacts of the proposed transaction since it involves the acquisition of a practice that is fee-for-service (private-pay) and does not participate in-network with any third-party payors including Medicare, Medicaid or commercial plans. | The parties state that there are no plans to reduce or eliminate existing services and/or participation in specific networks as a result of the transaction. | The parties state that given there are no anticipated adverse impacts of the transaction, the transaction does not involve commitments to mitigate adverse impacts. However, the parties expect the transaction to result in the preservation and expansion of clinical services by the practice due to the operational efficiencies that will be achieved. | |
| 15 | Aesthetic Plastic Surgery, P.C. (d/b/a NYBRA Plastic Surgery), NYBRA ASO, LLC ("ASO"), Plastics Management, LLC, NYBRA Seller, LLC |
A Long Island-based plastic surgery practice with four locations is entering into an agreement with an administrative services organization to receive administrative support. | 7/22/2025 | 8/26/2025 | Non-clinical assets are being bought and sold in this transaction, including the transfer of stock in the practice. Aesthetic Plastic Surgery d/b/a NYBRA Plastic Surgery ("Practice") is a reconstructive and cosmetic plastic surgery practice with four locations across New York and is the only party to the transaction that provides health care services. The practice offers services including breast reconstructive surgery, mastectomies, and aesthetic surgeries such as facial rejuvenation surgery and body contouring. The practice will transfer all non-clinical assets to NYBRA ASO, LLC ("ASO") and enter into an administrative services agreement, in which the ASO will provide administrative support to the practice. After the assets are transferred, Plastics Management, LLC will then purchase all applicable non-clinical assets from the ASO for cash. The owners of the practice will transfer all the stock of the practice to one existing physician owner, who will remain the sole owner of the practice after closing. The parties state that the purpose of the transaction is to achieve operational efficiencies and allow medical professionals to focus on patient care by outsourcing non-clinical business operations. The parties state that the mission of NYBRA will remain the same. |
The parties state that they do not expect any material changes to the day-to-day operations of NYBRA, including any changes to cost, quality, access, health equity, or compensation. | The parties state that NYBRA will continue to utilize the same providers at the same locations, and these providers will continue to provide the same high-quality services, as it does currently. | The parties state they do not expect any material changes to the day-to-day operations of NYBRA, including any changes to cost, quality, access, health equity, or compensation. | |
| 14 | Walgreens Boots Alliance, Inc. ("WBA"); Sycamore Partners Management, L.P. ("Sycamore") | Private equity firm is buying national pharmacy chain and its subsidiaries that offer health care services through urgent care and other businesses. | 7/18/2025 | 8/28/2025 | Sycamore Partners Management, L.P. ("Sycamore") is a private equity firm. Its affiliate will acquire all the voting securities of Walgreens Boots Alliance, Inc. ("WBA") through a merger. WBA has three New York State businesses: First, Walgreens is a retail pharmacy company that includes Walgreens Co. and its subsidiaries ("Walgreens"). Second, WBA is the parent of VillageMD, whose subsidiary is VillageMD. VillageMD provides management services to affiliated CityMD urgent care centers. Third, WBA provides practice management services to virtual care physician practices through Walgreens Health Services LLC ("Walgreens Health"), the ultimate parent of which is WBA. Walgreens is a nationwide pharmacy chain that has stores in all 50 states. Walgreens Co. and its subsidiaries have 469 locations in New York State. CityMD is an urgent care business that operates in New York and New Jersey and provides health care services including lab tests, vaccination, pediatric, and other health care services. It has 139 sites in New York State. SummitHealth is a Northeast-based company that provides health care services including ambulatory surgery, behavioral health, and cardiology care. It has 42 locations in New York State. WBA reported $147.7 B in sales in fiscal year 2024. Following the transaction closing, WBA and its subsidiaries will be controlled by Sycamore and its investment partners, and WBA will be removed from the public markets. |
The parties state there are no anticipated adverse impacts of the transaction on cost, quality, access, health equity, or competition. The parties state that Sycamore's consumer and retail expertise will help improve WBA's merchandising, marketing, and operational functions to revitalize Walgreens' stores and in turn enhance customer service and patient experience. | The parties state that there are no plans to reduce or eliminate existing services and/or participation in specific networks as a result of the transaction. The parties state that Sycamore does not plan to close any stores beyond those contemplated by WBA as part of the existing footprint optimization program and would expect that its operating improvements would enable WBA to maintain a larger store fleet and better serve New Yorkers. | The parties state this question is not applicable, as there are no anticipated adverse impacts of the transaction. | |
| 13 | Buyer parties: CVS Pharmacy, Inc., CVS Albany, LLC Seller parties: |
National retail pharmacy chain is buying prescription records and other assets from another business that operated as a full-service pharmacy prior to filing for bankruptcy. | 6/1/2025 | Transaction closed in waves between 07/01/2025 – 08/05/2025. | CVS Pharmacy, Inc. and CVS Albany, LLC will acquire certain assets from various Rite Aid parties. Rite Aid is currently undergoing bankruptcy proceedings and closing many stores nationwide. CVS' acquisition involves certain prescription records, inventory, and other related assets associated with certain retail pharmacy stores in New York State, pursuant to Sections 105, 363, and 365 of the Bankruptcy Code. CVS Pharmacy is a nationwide full-service pharmacy that provides prescription and other drug store services. It has stores in all 50 states and 575 locations in New York State. CVS Pharmacy is a subsidiary of CVS Health, which reported over $372 B in total revenue in 2024. Rite Aid is also a nationwide full-service pharmacy that provides prescription and other drug store services. It has stores in 15 states including New Jersey, California, and Pennsylvania and 202 locations in New York State. Nationwide, CVS will acquire the prescription files of 625 Rite Aid pharmacies across 15 states, and it will acquire and operate Rite Aid stores in Idaho, Washington, and Oregon. CVS parties say that through the transaction, it will help ensure customers' prescriptions are transitioned in an orderly manner either to a nearby CVS Pharmacy location or another pharmacy of the customer's choice if it is more convenient. |
The parties state that they do not anticipate any adverse impacts from the proposed transaction on cost, quality, access, health equity, or competition. | The parties state that they do not anticipate any adverse impacts from the proposed transaction on cost, quality, access, health equity, or competition. | The parties state this question is not applicable, given that the parties do not anticipate any adverse impacts from the proposed transaction on cost, quality, access, health equity, or competition. | |
| 12 | First transaction: BioMatrix Specialty Pharmacy, LLC and AdaptHealth Holdings LLC Second transaction: Upstate NewCo, LLC and Innovative Services Inc. d/b/a Upstate HomeCare |
National home medical equipment company is selling NY-based home infusion therapy provider with 8 NYS locations to a national specialty infusion pharmacy with 1 NYS location. | 5/9/2025 | 6/10/2025 | BioMatrix Specialty Pharmacy, LLC ("BioMatrix") will acquire Innovative Services Inc., d/b/a Upstate HomeCare, through two transactions. In the first transaction, BioMatrix will acquire 100% of the equity interests of Upstate Parent, LLC ("Parent") from AdaptHealth Holdings, LLC (a subsidiary of AdaptHealth Corporation, which is a network of medical equipment companies). In the second transaction, BioMatrix will acquire the stock of Upstate HomeCare. Both transactions are expected to close at the same time. BioMatrix is a nationwide independent specialty infusion pharmacy that provides services such as immunoglobulin and transplant support. It is licensed in all 50 states and has physical locations in Dewitt, New York and in states including California, Florida, New Jersey, and Texas. BioMatrix also holds several home health agency or other comparable licenses across the country. It is owned by a company managed by Frazier Healthcare Partners. Upstate HomeCare is a provider of home infusion therapy, specialty medications, and home medical equipment services, such as infusion and respiratory therapy. It has eight locations across New York State, including Upstate in Rochester, Syracuse, and Williamsville (near Buffalo), and Downstate in Elmsford, the Bronx, and Roslyn Heights. These sites are licensed as pharmacies and/or licensed home care service agencies. Following the closing of the second transaction, Biomatrix will be the sole member of Parent, which is the indirect owner of Upstate NewCo, LLC, the owner of 100% of the stock of Upstate HomeCare. In addition, Parent will be the upstream parent organization of Upstate HomeCare. The parties state that the purpose of the Transaction is to bring the resources and experience of BioMatrix in providing specialty infusion services to Upstate HomeCare to improve the delivery of services and to provide stability for the organization. |
The parties state that they do not anticipate that the Transactions will have any adverse impact on groups or individuals regarding cost, quality, access, health equity, or competition in the markets currently served. | The parties state that they do not anticipate that the Transactions will have any impact on the services offered and do not have plans to reduce or eliminate any such services. The parties do not anticipate that the Transactions will have any impact on participation in specific plan networks. | The parties state that since the parties do not anticipate any adverse impacts due to the Transactions, the requirement to make commitments to mitigate potential impacts does not apply to the Transactions. The parties are committed to monitoring and addressing any such impacts should they arise. | |
| 11 | Buyer Parties:
Seller Parties: Seller Holding Company and Dental Support Organizations:
Seller Practice Entities:
|
Northeast-based dental practice with 45 NYS locations is buying clinical assets from 13 dental practices in the Hudson Valley and the Capital District. The practice's dental services organization will purchase non-clinical assets from two dental support organizations. | 04/09/2025 | 05/08/2025 | There are both clinical and non-clinical asset purchases associated with this transaction involving multiple Buyers and Sellers: First, practice-based Buyer the Smilist Dental PLLC, which owns and operates numerous New York dental practices, will purchase certain clinical assets of the seller's 13 dental practices. The Smilist Dental PLLC provides dental services including exams and cleanings as well as orthodontics, crowns, and cosmetic dentistry procedures. It has 45 locations in New York State which are concentrated in New York City and Long Island as well as the Buffalo and Syracuse areas. The seller's 13 dental practices provide dental services in the Hudson Valley and Capital District, including three in the Albany area through Capital Region Dentistry PLLC and two in Kingston. Additionally in this transaction, a separate Buyer, the Smilist DSO, LLC, a dental support organization, will purchase non-clinical assets, of two other dental support organizations: HVNY DSO, LLC ("HVNY DSO") and CRNY DSO, LLC ("CRNY DSO"). Dental support organizations, or DSOs, typically provide administrative support to dental practices, such as administrative services and marketing. Finally, HVNY DSO, CRNY DSO, and certain Seller Practice Entities will contribute certain non-clinical assets to a third Buyer in this transaction, the holding company The Smilist SPE Holdings, LLC (the "Buyer Rollover Entity"), in exchange for equity in the Buyer Rollover Entity. |
The parties state that they do not anticipate the Transaction having any impact on (i) the scope, cost or quality of such dental services, (ii) any particular groups or individuals, (iii) health equity, or (iv) competition in the impacted market. | The parties state that they have no plans to eliminate services and/or participation in specific networks. | The parties state this question is not applicable – there are no plans to eliminate any services provided or reduce participation in any networks. | |
| 10 | Paulus Holdings Limited ("Paulus"); Alto Pharmacy Holdings, Inc. ("Alto") | A private Ireland-based holding company, which has subsidiaries that offer health testing and diagnostic services, as well as virtual pharmacy platform services, is buying a national pharmacy that specializes in fertility medications and other mail order pharmacy services that has 2 brick-and-mortar pharmacies in NYS. | 4/9/2025 | Early May 2025; transaction will not close sooner than 5/9/2025 | Paulus Holdings Limited ("Paulus") plans to acquire Alto Pharmacy Holdings, Inc. ("Alto") and its subsidiaries. Alto provides pharmacy services and mail order shipping of fertility medications. Alto also provides medications related to diabetes, sexual health, and heart health, such as hypertension. Alto does business in New York through its nationwide mail order services from its headquarters in California, as well as two physical pharmacies located in New York City and Plainview, NY. Paulus is a holding company whose subsidiaries include LetsGetChecked, Inc. ("LetsGetChecked") and Truepill Inc. ("Truepill). LetsGetChecked provides home health diagnostic test services for sexually transmitted diseases, PCOS, female hormones, and colon cancer. Truepill provides virtual pharmacy platform services for pharmacies. Truepill does business in New York through Postmeds Inc., d/b/a Truepill and its subsidiaries, Seven Hills Pharmacy LLC, Truepill NY LLC, and NMB Pharmacy Inc. Truepill NY LLC operates one location in Brooklyn, NY. LetsGetChecked provides services but does not have any physical locations in New York. Paulus plans to acquire and hold 100% of the issued and outstanding capital stock of Alto and its subsidiaries. The parties state that the purpose of the transaction is to combine the parties' complementary strengths resulting in improved pharmacy service offerings to customers and patients, improved delivery time, and cost reductions for patients in New York State and nationwide. The parties also state that the transaction will improve New York patients' access to fertility, weight loss and other medications. |
The parties state that they do not expect the transaction to have any adverse impact on groups or individuals regarding cost, quality, access, health equity, or competition in the markets they serve. | The parties state that they have no plans to reduce or eliminate services and/or participation in specific plan networks. | The parties state that because there are no anticipated adverse impacts as a result of the transaction, the parties have not identified any potential mitigation efforts, but they are committed to monitoring and addressing any such impacts should they arise. | |
| 9 | RGH Enterprises, LLC ("RGH") d/b/a Edgepark; ADS Parent, LLC ("ADS") |
National durable medical equipment supplier is buying a national distributor of diabetes-related products. Neither company has NYS locations but both ship medical equipment to individuals in the state. | 12/23/2024 | Early 2025; transaction will not close sooner than 01/23/2025 | RGH Enterprises, LLC, ("RGH") d/b/a Edgepark plans to acquire all outstanding equity of ADS Parent, LLC ("ADS"). RGH is owned by Cardinal Health, Inc. ("Cardinal"), which reported over $226 B in revenue in fiscal year 2024. ADS is owned by a company managed by Court Square Capital Partners. ADS is a national distributor of diabetes-related products, including glucose monitors, insulin vials and pumps and diabetes testing supplies. RGH is a national supplier of durable medical equipment, such as diabetes, breast pump, ostomy, and urological supplies. The parties state that the purpose of the transaction is to combine two complementary suppliers of home medical equipment and supplies to better serve patients and payors. Neither company has physical facilities in New York State. However, both companies ship medical equipment to New York. RGH has home medical equipment, pharmacy, and wholesaler licenses in New York. ADS and its subsidiaries, Advanced Diabetes Supply and US Med, LLC, are non-resident pharmacies, licensed to sell prescription goods in New York State. The transaction will occur through a merger of ADS and a wholly-owned subsidiary of RGH. |
The parties state that they do not expect the transaction to have any adverse impact on groups or individuals regarding cost, quality, access, health equity, or competition in the markets they serve. | The parties state that they have no plans to reduce or eliminate services and/or participation in specific plan networks. | The parties state that because there are no anticipated impacts as a result of the transaction, the parties have not identified any potential mitigation efforts, but they are committed to monitoring and addressing any such impacts should they arise. | |
| 8 | Rotech Healthcare Holdings, Inc. ("Rotech Parent"); Owens & Minor, Inc. ("OMI"); Hitchcock Merger Sub Inc. ("Merger Sub") |
A national health care logistics and distribution company, which provides products and services to support individuals in the hospital and at home with 10 locations in NYS, is buying a national home medical equipment company that specializes in respiratory products and has 6 locations in New York. | 11/21/2024 | Withdrawn | Rotech Healthcare Holdings, Inc., a Delaware corporation ("Rotech Parent"), the parent of Rotech Healthcare Inc. ("Rotech"), plans to merge with Hitchcock Merger Sub Inc., which is a wholly owned subsidiary of Owens & Minor, Inc. ("OMI"). Rotech is a home medical equipment company that is a nationwide provider of respiratory and home medical products including sleep apnea and nebulizers. Rotech does business in New York through various subsidiaries including Better Living Now, located in Long Island, New York. Rotech operates 6 locations in NYS all through its subsidiaries, such as Better Living Now. OMI does health care logistics and distribution. OMI does business in New York through its subsidiary, Apria Healthcare LLC, which has 10 locations throughout the state; nationally, Apria provides pharmacy, diabetes, sleep, and respiratory care. OMI will acquire and hold 100% of the outstanding voting securities of Rotech Parent. Rotech Parent will be the surviving corporation and a wholly owned subsidiary of OMI, integrated into OMI's Patient Direct segment. The transaction is anticipated to close in the first half of 2025. | The parties state that they do not anticipate any adverse impacts to groups or individuals regarding costs, quality, access, health equity, or competition in the impacted markets. | The parties state that they have not yet considered or analyzed any plans to close any branches or reduce operations. | The parties state that there are no anticipated detrimental impacts associated with the transaction, but they are committed to monitoring and addressing any such impacts should they arise. | |
| 7 | Albany Gastroenterology Consultants, PLLC; Gastrointestinal Care of Long Island, PLLC d/b/a Allied Digestive Health Medical Group of New York | National gastroenterology practice Allied Digestive Health Medical Group with 22 locations in NYS is buying New York-based gastroenterology practice Albany Gastroenterology Consultants, PLLC that has 4 NYS locations. | 09/20/2024 | 11/01/2024 | Gastrointestinal Care of Long Island, PLLC d/b/a Allied Digestive Health Medical Group of New York (GCLI, Buyer), a gastroenterology practice with 22 locations in New York and over 60 nationwide, proposes to acquire Albany Gastroenterology Consultants, PLLC (Albany PLLC, Seller). Buyer's offices are concentrated in Long Island and New York City, with many additional sites in New Jersey. Albany PLLC has two locations in the Capital Region of NY, one in Clifton Park and the other in Albany, and affiliations with several local hospitals. GCLI plans to buy Albany PLLC's assets. The parties assert that the purpose of the proposed transaction is to combine both practices into one group, as GCLI. | The parties state that they do not anticipate any adverse impacts to groups or individuals regarding costs, quality, access, health equity, or competition in the impacted markets. The parties state that they are not currently competitors in any way due to the geographic separation between their offices. | The parties state that they have no plans to eliminate or reduce any current gastroenterology services provided. | The parties state that there are no anticipated adverse impacts, and therefore the need to mitigate potential impacts does not apply. | |
| 6 | Quest Diagnostics Incorporated; Collaborative Care Holdings, LLC, a wholly-owned subsidiary of UnitedHealth Group Incorporated; and Affiliates for Collaborative Care Holdings, LLC, including: Optum Medical Care, P.C., CareMount Health Solutions, LLC, Crystal Run Healthcare Physicians LLP, Crystal Run Transformation Services, LLC, and ProHealth Medical Management, LLC |
A national laboratory services provider with 166 NYS patient service center locations is buying assets from a New York-based laboratory provider that has 39 locations in New York and is owned by UnitedHealth Group. | 8/28/2024 | 9/30/2024 | Under the proposed material transaction, Quest Diagnostics Incorporated (Buyer) seeks to purchase certain New York State laboratory assets of Collaborative Care Holdings, LLC (Seller), pursuant to an Asset Purchase Agreement. Quest currently serves as the primary reference laboratory for several of Collaborative Care Holdings' laboratories. Quest Diagnostics Incorporated is a Delaware corporation located in New Jersey and operates 166 patient service center locations in New York. Collaborative Care Holdings, LLC is a wholly-owned subsidiary of UnitedHealth Group Incorporated and located in Minnetonka, MN. It operates clinical and pathology laboratories, a processing center, and patient service centers in 39 locations within New York. Its affiliates include: Optum Medical Care, P.C., CareMount Health Solutions, LLC, Crystal Run Healthcare Physicians LLP, Crystal Run Transformation Services, LLC, and ProHealth Medical Management, LLC |
The Parties indicate they do not anticipate any adverse impact on patients. The Parties further state that the transaction is expected to improve cost, quality, access, health equity and competition in the marketplace, insofar as more patients will be able to utilize their in-network benefits through Quest's network of contracted health plans, including at least five health plans that are currently out of network with respect to Collaborative Care Holdings (MetroPlus, Health First, Fidelis, Magna Care and Oscar). Collaborative Care Holdings currently participates with CDPHP (Capital District Physician Health Plan), and Quest Diagnostics Incorporated does not. However, the Parties state that beneficiaries covered by CDPHP represent a small portion of the total volume of laboratory tests performed by the in-scope laboratories (less than 1% of volume for each), and therefore the impact is expected to be minimal. |
The Parties indicate that there are no plans to reduce or eliminate services. The Parties further state that the transaction is expected to improve cost, quality, access, health equity and competition in the marketplace, insofar as more patients will be able to utilize their in-network benefits through Quest's network of contracted health plans, including at least five health plans that are currently out of network with respect to Collaborative Care Holdings (MetroPlus, Health First, Fidelis, Magna Care and Oscar). The Parties further indicate that patients will also have increased access to care, given the size of Quest Diagnostic's network of patient service centers and test menu. | The Parties do not indicate any commitments specific to this proposed transaction. However, the Parties generally note that Quest Diagnostics, along with its Quest Diagnostics Foundation, have launched an initiative focused on reducing health disparities in underserved communities through a combination of testing services, education programs, alliances and financial support (the "Quest for Health Equity" initiative). Initiatives include, for example, providing free lab testing services for populations served by Federally Qualified Health Centers. The Parties do not state whether any new projects under the "Quest for Health Equity" will be launched in response to this transaction, however. | |
| 5 | Valence ACP Intermediary Holdco, Inc.; Health Insurance Plan of Greater New York (a subsidiary of EmblemHealth, Inc., which is a subsidiary of EmblemHealth Services Company, LLC); AdvantageCare Physicians Support Services, LLC (New Company); AdvantageCare Physicians, P.C.; SIUC Medical, P.C.; and HCS-Girling Holdco, LLC |
A New York-based health insurance plan owned by national nonprofit health insurance plan EmblemHealth is forming a new management services organization (MSO). This MSO is buying some of the companies' assets and will provide administrative support to 2 physician practices that are also affiliated with EmblemHealth. | 07/02/2024 | 08/01/2024 | Under the proposed transaction, Valence ACP Intermediary Holdco, Inc. (Valence) and Health Insurance Plan of Greater New York (HIP), which is a subsidiary of EmblemHealth, Inc., whose parent is EmblemHealth Services Company, LLC, will form a new Management Services Organization (MSO) to be known as AdvantageCare Physician Support Services, LLC. HCS-Girling Holdco, LLC is a sister company of Valence and both are under common ownership. The new MSO is being formed under the transaction to support two physician practices currently affiliated with EmblemHealth, Inc.: AdvantageCare Physicians, P.C. (ACPNY) and SIUC Medical, P.C. (SIUC). The new MSO will purchase certain assets from HIP and ACPNY and, pursuant to a Management Services Agreement to be entered into by the Parties, will provide administrative and business support services to ACPNY and SIUC. |
The Parties state that they have no plans to eliminate services and/or reduce participation in specific networks. | The Parties state that, ACPNY and SIUC will continue to provide primary and specialty care services. The Parties indicate that the formation of the MSO will "allow[] the practices to focus on patient care, enhancing their clinical model and expanding access to primary and specialty care services." The Parties indicate they do not anticipate the transaction having any impact on the scope, cost or quality of such services, nor on any particular groups or individuals, on health equity, or on competition in the impacted market. The Parties further state that all physicians who currently provide services for or on behalf of the practices will continue to be employed or contracted by the practices following the transaction's closing. |
The Parties state that commitments to mitigate potential impacts is not applicable, as the Parties state there are no plans to eliminate any services provided or reduce participation in any network affiliations. | |
| 4 | Invitae Corporation; Labcorp Genetics, Inc. (a subsidiary of Laboratory Corporation of America Holdings) |
A national laboratory services company is buying a California-based company that provides genetic testing and that filed for bankruptcy. | 06/04/2024 | 08/23/2024 | Invitae Corporation (Seller) is a California-based health care company that delivers genetic testing services, digital health solutions and health data services to patients nationwide, including in New York State. Seller offers genetic testing across multiple clinical areas, including hereditary cancers, precision oncology, and rare diseases. Labcorp Genetics, Inc. (Buyer) is a Delaware corporation and a wholly-owned subsidiary of Laboratory Corporation of America Holdings. Laboratory Corporation of America Holdings is the guarantor to the transaction. On February 13, 2024, Seller filed for Chapter 11 bankruptcy. The goal of the proposed transaction is for Seller to sell its assets to pay its creditors and settle its executory debts, while maintaining patient access to Seller's current services. The Parties assert that the transaction will allow Seller to avoid conversion of its Chapter 11 case to a Chapter 7 liquidation, and further state that the transaction is essential to avoid further depletion of Seller's cash reserves, which would impair Seller's ability to remain administratively solvent. |
No anticipated adverse impacts. The Parties indicate that the Seller's workforce would be adversely impacted if the proposed transaction does not occur, insofar as Seller would cease operations without the proposed acquisition by Buyer. As part of the transaction, Buyer has committed to hiring at least 95% of Seller's employees at compensation and benefit levels at least as favorable as those the employees receive pre-closing | No anticipated adverse impacts. The Parties indicate the proposed transaction will allow continued access to genetic testing services and technologies for the Seller's patients and allow further patients to benefit from the genetic testing services and technologies developed by Seller through the proposed new ownership by Buyer. | The Parties indicate that there are no anticipated adverse impacts associated with the transaction, but state that the Parties are committed to monitoring and addressing any such impacts should they arise. | |
| 3 | Gramercy Park Administrative Services, LLC (a subsidiary of Surgery Partners); GPDDC, LLC |
New York administrative services provider is buying assets from a New York City-based ambulatory surgery center specializing in gastroenterology services. In addition to selling the assets, the seller will pay a yearly fee to get ongoing business support services. | 03/08/2024 | 05/03/2024 | The Seller, GPDDC, LLC, is currently licensed by the NYS Department of Health to operate as a Diagnostic and Treatment Center-Ambulatory Surgery Center (ASC) specializing in gastroenterology services. The Seller's health care services are currently provided in New York City within zip code 10003. The Buyer, Gramercy Park Administrative Services, LLC, is an administrative services provider. The transaction will involve the sale of certain non-clinical assets of the Seller/ASC to the Buyer in exchange for cash and equity in the Buyer. The Parties will enter into an Administrative Services Agreement, under which the Buyer will provide business support services to the Seller/ASC in exchange for an annual fee. The Parties state that the purpose of the transaction is to facilitate the Seller/ASC's interest in selling certain of its non-clinical assets and receiving business support services, as well as the Buyer's interest in purchasing certain of those non-clinical assets and furnishing business support services to the Seller/ASC. |
The Parties do not anticipate any impact on cost, quality, access, health equity, or competition in the impacted markets. | The Parties indicate that the transaction will not affect the services provided by the Seller/ASC or the patient population it currently serves. The Parties further indicate that all physicians who currently provide services at the ASC will continue to do so following the Transaction Closing. |
The Parties do not expect any impacts as a result of the Transaction, and therefore have not identified any potential mitigation efforts or other commitments. | |
| 2 | Quest Diagnostics Incorporated, Inc.; Lenco Diagnostic Laboratories, Inc. |
National laboratory services company with 154 patient locations in New York is buying assets such as patient accounts from a Brooklyn-based laboratory business with 20 NYS patient service center locations. | 01/12/2024 | 02/12/2024 | Under the proposed material transaction, Quest Diagnostics Incorporated (Buyer) seeks to purchase certain assets of Lenco Diagnostic Labs (Seller) (collectively, the Parties), pursuant to an Asset Purchase Agreement. Buyer is a Delaware corporation located in New Jersey and operates 154 patient service center locations in New York. Seller is a New York corporation located in Brooklyn, New York and operates 20 patient service center locations in New York. Seller conducts a clinical and anatomic pathology laboratory business performing services for individuals, physician practices, ordering providers and other customers. Key assets proposed to be acquired include but are not limited to: (i) all customer accounts (i.e., business accounts of health care providers who ordered services from Seller within the 12 months preceding the transaction); (ii) all contractor and supplier lists; (iii) all tangible property, leaseholds, inventory, and equipment; (iv) all standing orders; (vi) all trade names, product names, and logos; and (vii) intellectual property, including patient information. Among other excluded assets, Seller's laboratory would not be acquired under the proposed transaction. Seller may continue using the trade name "Lenco Diagnostic Laboratories, Inc." for up to 24 months following the closing, but thereafter shall use a new corporate name agreed to by Buyer. The proposed closing date is February 12, 2024. |
The Parties assert there will be no adverse impact on NYS patients and state that consumer choice and access will increase as a result of the transaction, insofar as the post-transaction entity will participate in more commercial health insurance plans than Seller currently participates with. Additionally, the Parties assert that current patients of Seller will have access to additional service locations through the Quest health system. | The Parties indicate that there will be no impact on services and assert that all patient services will remain intact post-transaction. The Department notes that the laboratory currently owned and operated by Seller is not subject to the asset purchase agreement, and, per the proposed Asset Purchase Agreement, Seller has not received any written or verbal indication from the Centers for Medicare and Medicaid Services (CMS) or any other payor that they intend to materially reduce the amount paid to Seller for any of its laboratory services, or terminate Seller as a participating or non-participating provider of Testing. On 02/08/24, the Parties shared the following additional information relating to Service Impact: 10% of patients currently tested by Seller access services through its patient service centers; 4 of Seller's patient service locations will remain open with the remaining 16 patient service centers to be closed; and For those patient service locations to be closed, alternative Buyer locations are suggested, averaging less than 1 mile from the Seller location to be closed. |
||
| 1 | West Side GI, LLC West Side GI Administrative Services Organization, LLC | An administrative services organization is buying non-clinical assets from a New York-based diagnostic and treatment center providing gastroenterology services. In addition to selling the assets, the seller will pay a yearly fee to get ongoing business support services. | 08/25/2023 | 09/29/2023 | Under the proposed material transaction, West Side GI, LLC, (WSGI), licensed to operate as a Diagnostic and Treatment Center in New York State, will sell certain non-clinical assets to West Side GI Administrative Services Organization, LLC (Buyer) in exchange for cash and rollover equity. WSGI and Buyer will enter into an Administrative Services Agreement in which the Buyer will provide support services to WSGI in exchange for an annual fee. This transaction is intended to facilitate WSGI's sale of certain non-clinical asset in exchange for business support services as well as the Buyer's interest in purchasing such assets and providing such business services. | No public impact | West Side GI currently provides gastroenterology and related services. WSGI sees Medicare and Medicaid patients, patients with commercial insurance, and charity care patients. WSGI is licensed to operate as a Diagnostic and Treatment Center Westside GI does not plan to reduce or eliminate any existing services under the proposed material transaction. |
